



Clinical trial results:

A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2019-003304-12 |
| Trial protocol | DE GB |
| Global end of trial date | 26 July 2022 |

Results information

| | |
|--------------------------------|-----------------|
| Result version number | v1 (current) |
| This version publication date | 04 October 2023 |
| First version publication date | 04 October 2023 |

Trial information

Trial identification

| | |
|-----------------------|-------------|
| Sponsor protocol code | D9182C00001 |
|-----------------------|-------------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04212169 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | AstraZeneca |
| Sponsor organisation address | 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA |
| Public contact | Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com |
| Scientific contact | Global Clinical Lead, AstraZeneca, +1 18772409479, information.center@astrazeneca.com |

Notes:

Paediatric regulatory details

| | |
|--|----|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|------------------|
| Analysis stage | Final |
| Date of interim/final analysis | 18 November 2022 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 04 February 2022 |
| Global end of trial reached? | Yes |
| Global end of trial date | 26 July 2022 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

To assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD.

Protection of trial subjects:

The study was performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Council for Harmonisation (ICH)/Good Clinical Practice (GCP), and applicable regulatory requirements. All participant must meet all inclusion criteria and not meet any exclusion criteria before receiving investigational product. IDMC was formed to monitor potential risk in the study.

Background therapy:

Participants who meet the eligibility (inclusion/exclusion) criteria will discontinue use of topical corticosteroids and topical calcineurin inhibitorss at Visit 2. Subjects will be required to apply moisturizers twice daily for at least 7 days before randomization at Visit 3 (Day 1) with a minimum of 85% compliance

Evidence for comparator:

Not applicable as there was no comparator arm in the study

| | |
|---|------------------|
| Actual start date of recruitment | 09 December 2019 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects**Subjects enrolled per country**

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Australia: 2 |
| Country: Number of subjects enrolled | Germany: 11 |
| Country: Number of subjects enrolled | Poland: 16 |
| Country: Number of subjects enrolled | Spain: 12 |
| Country: Number of subjects enrolled | United Kingdom: 91 |
| Country: Number of subjects enrolled | United States: 16 |
| Worldwide total number of subjects | 148 |
| EEA total number of subjects | 39 |

Notes:

Subjects enrolled per age group

| | |
|--|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 | 0 |

| | |
|--|-----|
| wk | |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 148 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

The study was conducted in 6 countries between 19 Dec 2019 and 20 Sep 2022. A total of 329 participants were screened in the study.

Pre-assignment

Screening details:

Out of 329 participants, 148 were randomised and treated in the study with 3:1:1:3 overall ratio to receive either placebo (56 subjects), MEDI3506 dose 1 (19 subjects), MEDI3506 dose 2 (18 subjects), or MEDI3506 dose 3 (55 subjects).

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor |

Blinding implementation details:

Subject was randomised using an interactive web response system to receive either of 3 doses of MEDI3506 or placebo. Participants, investigators and the sponsors are blinded with regard to the actual dose information.

Arms

| | |
|------------------------------|---------|
| Are arms mutually exclusive? | Yes |
| Arm title | Placebo |

Arm description:

Pooled Placebo

| | |
|--|------------------------|
| Arm type | Placebo |
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Given subcutaneously on Day 1, Day 29, Day 57 and Day 85

| | |
|------------------|-----------------|
| Arm title | MEDI3506 Dose 1 |
|------------------|-----------------|

Arm description:

MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI3506 Dose 1 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Given subcutaneously on Day 1, Day 29, Day 57 and Day 85.

| | |
|------------------|-----------------|
| Arm title | MEDI3506 Dose 2 |
|------------------|-----------------|

Arm description:

MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks

| | |
|----------|--------------|
| Arm type | Experimental |
|----------|--------------|

| | |
|--|------------------------|
| Investigational medicinal product name | MEDI3506 Dose 2 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |
| Dosage and administration details: | |
| Given subcutaneously on Day 1, Day 29, Day 57 and Day 85 | |
| Arm title | MEDI3506 Dose 3 |

Arm description:

MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks

| | |
|--|------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | MEDI3506 Dose 3 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Solution for injection |
| Routes of administration | Subcutaneous use |

Dosage and administration details:

Given subcutaneously on Day 1, Day 29, Day 57 and Day 85

| Number of subjects in period 1 | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 |
|---------------------------------------|---------|-----------------|-----------------|
| Started | 56 | 19 | 18 |
| Completed | 42 | 16 | 13 |
| Not completed | 14 | 3 | 5 |
| Consent withdrawn by subject | 10 | 2 | 5 |
| Adverse event, non-fatal | - | - | - |
| Lost to follow-up | 1 | - | - |
| Other reason, unspecified | 3 | 1 | - |

| Number of subjects in period 1 | MEDI3506 Dose 3 |
|---------------------------------------|-----------------|
| Started | 55 |
| Completed | 42 |
| Not completed | 13 |
| Consent withdrawn by subject | 7 |
| Adverse event, non-fatal | 2 |
| Lost to follow-up | 2 |
| Other reason, unspecified | 2 |

Baseline characteristics

Reporting groups

| | |
|---|-----------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Pooled Placebo | |
| Reporting group title | MEDI3506 Dose 1 |
| Reporting group description: | |
| MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks | |
| Reporting group title | MEDI3506 Dose 2 |
| Reporting group description: | |
| MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks | |
| Reporting group title | MEDI3506 Dose 3 |
| Reporting group description: | |
| MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks | |

| Reporting group values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 |
|---|---------|-----------------|-----------------|
| Number of subjects | 56 | 19 | 18 |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-35 years) | 39 | 16 | 9 |
| From 36-75 years | 17 | 3 | 9 |
| Age Continuous | | | |
| Units: Years | | | |
| arithmetic mean | 32.3 | 28.7 | 37.9 |
| standard deviation | ± 11.4 | ± 8.9 | ± 14.3 |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 27 | 8 | 7 |
| Male | 29 | 11 | 11 |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 |
| ASIAN | 8 | 5 | 3 |
| BLACK OR AFRICAN AMERICAN | 1 | 1 | 2 |
| MULTIPLE CATEGORIES CHECKED | 1 | 0 | 1 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 |
| OTHER | 0 | 0 | 1 |
| WHITE | 46 | 13 | 11 |
| Region of Enrollment | | | |
| Units: Subjects | | | |
| USA | 6 | 0 | 3 |
| Australia | 0 | 0 | 1 |
| Germany | 5 | 1 | 3 |
| Spain | 7 | 0 | 0 |
| United Kingdom | 34 | 13 | 9 |
| Poland | 4 | 5 | 2 |

| | | | |
|---|-------|---------|---------|
| Eczema Area and Severity Index (EASI) score | | | |
| Eczema Area and Severity Index (EASI) score is a composite score of area of involvement and severity score of 4 different body areas. The severity score is based on erythema, oedema/papulation, excoriation and lichenification of 4 body areas which are head, trunk, upper limbs and lower limbs. The score ranges between 0 to 72 points. Higher EASI score indicates more severe disease. | | | |
| Units: Scores on a scale | | | |
| arithmetic mean | 28.81 | 28.94 | 28.36 |
| standard deviation | ± 8.9 | ± 11.66 | ± 11.87 |

| Reporting group values | MEDI3506 Dose 3 | Total | |
|---|-----------------|-------|--|
| Number of subjects | 55 | 148 | |
| Age categorical | | | |
| Units: Subjects | | | |
| Adults (18-35 years) | 32 | 96 | |
| From 36-75 years | 23 | 52 | |
| Age Continuous | | | |
| Units: Years | | | |
| arithmetic mean | 34.6 | - | |
| standard deviation | ± 11.8 | - | |
| Sex: Female, Male | | | |
| Units: Participants | | | |
| Female | 25 | 67 | |
| Male | 30 | 81 | |
| Race (NIH/OMB) | | | |
| Units: Subjects | | | |
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | |
| ASIAN | 6 | 22 | |
| BLACK OR AFRICAN AMERICAN | 2 | 6 | |
| MULTIPLE CATEGORIES CHECKED | 0 | 2 | |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | |
| OTHER | 2 | 3 | |
| WHITE | 45 | 115 | |
| Region of Enrollment | | | |
| Units: Subjects | | | |
| USA | 7 | 16 | |
| Australia | 1 | 2 | |
| Germany | 2 | 11 | |
| Spain | 5 | 12 | |
| United Kingdom | 35 | 91 | |
| Poland | 5 | 16 | |
| Eczema Area and Severity Index (EASI) score | | | |
| Eczema Area and Severity Index (EASI) score is a composite score of area of involvement and severity score of 4 different body areas. The severity score is based on erythema, oedema/papulation, excoriation and lichenification of 4 body areas which are head, trunk, upper limbs and lower limbs. The score ranges between 0 to 72 points. Higher EASI score indicates more severe disease. | | | |
| Units: Scores on a scale | | | |
| arithmetic mean | 32.3 | - | |
| standard deviation | ± 10.86 | - | |

End points

End points reporting groups

| | |
|---|-----------------|
| Reporting group title | Placebo |
| Reporting group description: | |
| Pooled Placebo | |
| Reporting group title | MEDI3506 Dose 1 |
| Reporting group description: | |
| MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks | |
| Reporting group title | MEDI3506 Dose 2 |
| Reporting group description: | |
| MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks | |
| Reporting group title | MEDI3506 Dose 3 |
| Reporting group description: | |
| MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks | |

Primary: Percent Change from Baseline to Week 16 in EASI score

| | |
|---|---|
| End point title | Percent Change from Baseline to Week 16 in EASI score |
| End point description: | |
| The EASI evaluates 4 anatomic regions for severity and extent of key disease signs and focuses on the acute and chronic signs of inflammation (ie, erythema, edema, papulation, excoriation, and lichenification). The maximum score is 72, with higher values indicating more severe disease. Analysis was performed using mixed effect model for repeated measures and MCP-mod dose response model. | |
| End point type | Primary |
| End point timeframe: | |
| Week 16 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|------------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 55 | 19 | 17 | 54 |
| Units: Percentage of change from baseline | | | | |
| least squares mean (standard error) | | | | |
| Repeated measures mixed model | -51.31 (± 5.214) | -50.03 (± 7.419) | -45.43 (± 8.402) | -53.02 (± 4.858) |
| MCP-mod dose response model | 0 (± 0) | 0 (± 0) | 0 (± 0) | 0 (± 0) |

Statistical analyses

| | |
|----------------------------|--------------------------------------|
| Statistical analysis title | Difference in % change in EASI score |
| Comparison groups | MEDI3506 Dose 1 v Placebo |

| | |
|---|--------------------------------|
| Number of subjects included in analysis | 74 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.888 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 1.27 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -13.67 |
| upper limit | 16.22 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 8.981 |

| | |
|---|--------------------------------------|
| Statistical analysis title | Difference in % change in EASI score |
| Comparison groups | MEDI3506 Dose 3 v Placebo |
| Number of subjects included in analysis | 109 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.807 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | -1.72 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -13.38 |
| upper limit | 9.95 |
| Variability estimate | Standard error of the mean |
| Dispersion value | 7.014 |

| | |
|---|--------------------------------------|
| Statistical analysis title | Difference in % change in EASI score |
| Comparison groups | MEDI3506 Dose 2 v Placebo |
| Number of subjects included in analysis | 72 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.549 |
| Method | Mixed models analysis |
| Parameter estimate | Mean difference (final values) |
| Point estimate | 5.87 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | -10.36 |
| upper limit | 22.1 |

| | |
|----------------------|----------------------------|
| Variability estimate | Standard error of the mean |
| Dispersion value | 9.756 |

Secondary: Percentage of Subjects achieving a 90% reduction from baseline in EASI Score at week 16

| | |
|-----------------|---|
| End point title | Percentage of Subjects achieving a 90% reduction from baseline in EASI Score at week 16 |
|-----------------|---|

End point description:

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 90% reduction from baseline in EASI score.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| Number of participants achieving reduction | 0 | 0 | 1 | 3 |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of Subjects achieving a 75% reduction from baseline in EASI Score at week 16

| | |
|-----------------|---|
| End point title | Percentage of Subjects achieving a 75% reduction from baseline in EASI Score at week 16 |
|-----------------|---|

End point description:

To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 75% reduction from baseline in EASI score.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| Number of participants achieving reduction | 4 | 2 | 1 | 10 |

Statistical analyses

| | |
|---|---------------------------|
| Statistical analysis title | Odds ratio |
| Comparison groups | MEDI3506 Dose 1 v Placebo |
| Number of subjects included in analysis | 75 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.6396 |
| Method | Fisher exact |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 1.53 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.19 |
| upper limit | 9.94 |

| | |
|---|---------------------------|
| Statistical analysis title | Odds ratio |
| Comparison groups | MEDI3506 Dose 3 v Placebo |
| Number of subjects included in analysis | 111 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.0935 |
| Method | Regression, Logistic |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 2.89 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.91 |
| upper limit | 10.49 |

| | |
|-----------------------------------|---------------------------|
| Statistical analysis title | Odds ratio |
| Comparison groups | MEDI3506 Dose 2 v Placebo |

| | |
|---|-----------------|
| Number of subjects included in analysis | 74 |
| Analysis specification | Pre-specified |
| Analysis type | |
| P-value | = 0.9999 |
| Method | Fisher exact |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 0.76 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.03 |
| upper limit | 6.38 |

Secondary: Percentage of Subjects achieving a 50% reduction from baseline in EASI Score at week 16

| | |
|--|---|
| End point title | Percentage of Subjects achieving a 50% reduction from baseline in EASI Score at week 16 |
| End point description: To further assess the effects of MEDI3506 compared with placebo on AD disease severity, in adult subjects with moderate-to-severe AD. Responders are subjects who achieved at least 50% reduction from baseline in EASI score. | |
| End point type | Secondary |
| End point timeframe: Week 16 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| Number of participants achieving reduction | 12 | 5 | 5 | 16 |

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of subjects achieving an IGA of 0 (clear) or 1 (almost clear) with at least a 2 grade reduction from baseline score at Week 16

| | |
|--|---|
| End point title | Percentage of subjects achieving an IGA of 0 (clear) or 1 (almost clear) with at least a 2 grade reduction from baseline score at Week 16 |
| End point description: The IGA allows investigators to assess overall AD disease severity at 1 given time point and consists of a 5-point severity scale from clear to very severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease). | |
| End point type | Secondary |

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| IGA response | 1 | 1 | 0 | 5 |
| IGA response using MCP-Mod dose-response analysis | 0 | 0 | 0 | 0 |

Statistical analyses

| | |
|---|---------------------------|
| Statistical analysis title | Odds ratio |
| Comparison groups | MEDI3506 Dose 1 v Placebo |
| Number of subjects included in analysis | 75 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.445 |
| Method | Fisher exact |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 3.06 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.08 |
| upper limit | 119.65 |

| | |
|---|---------------------------|
| Statistical analysis title | Odds ratio |
| Comparison groups | MEDI3506 Dose 3 v Placebo |
| Number of subjects included in analysis | 111 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.1132 |
| Method | Fisher exact |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 5.5 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0.75 |
| upper limit | 130.35 |

| | |
|---|---------------------------|
| Statistical analysis title | Odds ratio |
| Comparison groups | MEDI3506 Dose 2 v Placebo |
| Number of subjects included in analysis | 74 |
| Analysis specification | Pre-specified |
| Analysis type | superiority |
| P-value | = 0.9999 |
| Method | Fisher exact |
| Parameter estimate | Odds ratio (OR) |
| Point estimate | 0 |
| Confidence interval | |
| level | 90 % |
| sides | 2-sided |
| lower limit | 0 |
| upper limit | 28 |

Secondary: Percentage of subjects achieving a reduction of ≥ 3 from baseline to Week 16 in weekly mean of daily peak pruritus NRS

| | |
|------------------------|--|
| End point title | Percentage of subjects achieving a reduction of ≥ 3 from baseline to Week 16 in weekly mean of daily peak pruritus NRS |
| End point description: | Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean. |
| End point type | Secondary |
| End point timeframe: | Week 16 |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|-----------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | 9 | 3 | 3 | 12 |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in weekly mean of daily peak pruritus NRS

| | |
|-----------------|---|
| End point title | Change from baseline to Week 16 in weekly mean of daily peak pruritus NRS |
|-----------------|---|

End point description:

Peak pruritus (ie, worst itch experienced in the previous 24 hours) assessed using an Numerical Rating Scale (NRS; 0 to 10) with 0 = no itch and 10 = worst imaginable itch. The daily assessments were summarised as a weekly mean.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 28 | 14 | 10 | 29 |
| Units: Scores on a scale | | | | |
| arithmetic mean (standard deviation) | -1.98 (± 2.38) | -1.18 (± 2.72) | -2.12 (± 1.61) | -2.49 (± 2.01) |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in weekly mean of daily peak skin pain NRS

| | |
|-----------------|--|
| End point title | Change from baseline to Week 16 in weekly mean of daily peak skin pain NRS |
|-----------------|--|

End point description:

Skin pain (ie, worst skin pain experienced in the previous 24 hours) assessed using an NRS (0 to 10) with 0 = no pain and 10 = worst imaginable pain. The daily assessments were summarised as a weekly mean.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 41 | 16 | 12 | 40 |
| Units: Scores on a scale | | | | |
| arithmetic mean (standard deviation) | -1.44 (± 2.39) | -1.66 (± 2.62) | -1.52 (± 1.61) | -1.63 (± 2.30) |

Statistical analyses

No statistical analyses for this end point

Secondary: SCORAD: Percent change from baseline to Week 16

| | |
|--|---|
| End point title | SCORAD: Percent change from baseline to Week 16 |
| End point description: SCORAD is a clinical tool for assessing the severity of AD that evaluates the extent and intensity of AD lesions, in addition to subjective symptoms. The maximum total score is 103, with higher values indicating more severe disease. | |
| End point type | Secondary |
| End point timeframe: Week 16 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|------------------|------------------|------------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 35 | 15 | 12 | 40 |
| Units: Percentage of change from baseline | | | | |
| arithmetic mean (standard deviation) | -31.79 (± 25.09) | -29.88 (± 23.14) | -36.22 (± 25.34) | -39.42 (± 25.44) |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in percentage body surface area (BSA) affected by AD

| | |
|--|--|
| End point title | Change from baseline to Week 16 in percentage body surface area (BSA) affected by AD |
| End point description: Change in percentage of body surface area (BSA) affected by AD from baseline at week 16. | |
| End point type | Secondary |
| End point timeframe: Week 16 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|------------------|------------------|-----------------|------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 37 | 15 | 13 | 40 |
| Units: Percentage of body surface area | | | | |
| arithmetic mean (standard deviation) | -17.81 (± 17.09) | -11.07 (± 10.92) | -9.46 (± 13.23) | -23.13 (± 19.35) |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in DLQI

| | |
|-----------------|---|
| End point title | Change from baseline to Week 16 in DLQI |
|-----------------|---|

End point description:

The Dermatology Life Quality Index (DLQI) is a 10-item, patient- completed, health-related quality of life assessment of dermatology conditions with a recall period of 1 week. Each item is scored on a 4-point Likert scale with 0 = not at all /not relevant, 1 = a little, 2 = a lot, and 3 = very much. The score from each item is summed, and the maximum total score is 30 while the minimum score is 0. Higher score means highest (adverse) effect on participant's life.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 38 | 15 | 12 | 40 |
| Units: Scores on scale | | | | |
| arithmetic mean (standard deviation) | -2.9 (± 5.3) | -2.1 (± 6.5) | -2.4 (± 4.9) | -2.7 (± 4.9) |

Statistical analyses

No statistical analyses for this end point

Secondary: Patient description of Atopic Dermatitis or eczema from Patient Global Impression of Severity at Week 16

| | |
|-----------------|--|
| End point title | Patient description of Atopic Dermatitis or eczema from Patient Global Impression of Severity at Week 16 |
|-----------------|--|

End point description:

The Patient Global Impression of Severity (PGI-S) is a tool that allows patients to rate the severity of a condition over the past 7 days with response options of "No symptoms", "Very mild", "Mild", "Moderate", "Severe" and "Very severe".

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| No symptoms No in category at week 16 | 1 | 0 | 1 | 1 |
| Very mild No in category at week 16 | 5 | 0 | 5 | 10 |
| Mild No in category at week 16 | 9 | 4 | 2 | 8 |
| Moderate No in category at week 16 | 11 | 5 | 1 | 14 |
| Severe No in category at week 16 | 11 | 4 | 2 | 6 |

| | | | | |
|--|----|---|---|----|
| Very severe No in category at week 16 | 1 | 2 | 1 | 1 |
| Missing data No in category at week 16 | 18 | 4 | 6 | 15 |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in POEM

| | |
|--|---|
| End point title | Change from baseline to Week 16 in POEM |
| End point description: | |
| The Patient-Oriented Eczema Measure (POEM) is a 7-item questionnaire for assessing disease symptoms including dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping occurring in the past week. Each item is scored on a 5-point scale with 0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = every day. The total POEM score is calculated by summing the score of each item resulting in a maximum of 28 and a minimum of 0, with higher values indicating severe disease | |
| End point type | Secondary |
| End point timeframe: | |
| Week 16 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 38 | 15 | 12 | 40 |
| Units: Scores on scale | | | | |
| arithmetic mean (standard deviation) | -5.4 (± 7.9) | -2.5 (± 4.8) | -3.7 (± 8.7) | -6.3 (± 6.9) |

Statistical analyses

No statistical analyses for this end point

Secondary: Change from baseline to Week 16 in 5-D itch

| | |
|--|---|
| End point title | Change from baseline to Week 16 in 5-D itch |
| End point description: | |
| The 5-D Itch Scale is a questionnaire consisting of 5 items used specifically to measure the course of itch by asking for the degree, duration, disability and distribution of the pruritus within the last 2 weeks. The scores from each item are summed, with maximum score of 25 and minimum score of 5. Higher score represent worse outcome | |
| End point type | Secondary |
| End point timeframe: | |
| Week 16 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 38 | 15 | 12 | 40 |
| Units: Scores on scale | | | | |
| arithmetic mean (standard deviation) | -3.0 (± 4.9) | -3.0 (± 2.6) | -3.8 (± 3.4) | -4.0 (± 5.1) |

Statistical analyses

No statistical analyses for this end point

Secondary: Occurrence of Adverse Events

| | |
|--|------------------------------|
| End point title | Occurrence of Adverse Events |
| End point description: To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD. | |
| End point type | Secondary |
| End point timeframe: up to 24 weeks | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participant | | | | |
| At least one adverse event | 37 | 9 | 14 | 32 |
| At least one investigational product related event | 7 | 3 | 7 | 8 |
| At least one event of ≥ grade 3 severity | 7 | 2 | 2 | 5 |
| At least one serious event | 2 | 0 | 2 | 1 |
| At least one IP related serious event | 0 | 0 | 1 | 0 |

Statistical analyses

No statistical analyses for this end point

Secondary: Oral or tympanic temperature taken during vital signs assessment

| | |
|--|--|
| End point title | Oral or tympanic temperature taken during vital signs assessment |
| End point description: Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD. | |
| End point type | Secondary |
| End point timeframe: Baseline, week 16 and week 24 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: degrees C | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 36.46 (± 0.35) | 36.43 (± 0.52) | 36.41 (± 0.43) | 36.52 (± 0.39) |
| Week 16 | 36.49 (± 0.36) | 36.71 (± 0.41) | 36.50 (± 0.32) | 36.47 (± 0.39) |
| Week 24 | 36.44 (± 0.43) | 36.63 (± 0.50) | 36.55 (± 0.42) | 36.51 (± 0.37) |

Statistical analyses

No statistical analyses for this end point

Secondary: Systolic blood pressure taken during vital signs assessment

| | |
|--|---|
| End point title | Systolic blood pressure taken during vital signs assessment |
| End point description: Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD. | |
| End point type | Secondary |
| End point timeframe: Baseline, week 16 and week 24 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: mmHg | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 117.7 (± 12.9) | 119.3 (± 9.2) | 123.8 (± 9.9) | 121.5 (± 12.5) |
| Week 16 | 117.8 (± 9.6) | 117.3 (± 7.2) | 120.7 (± 13.6) | 119.8 (± 10.6) |
| Week 24 | 118.9 (± 11.1) | 117.6 (± 11.4) | 120.1 (± 15.1) | 120.6 (± 12.1) |

Statistical analyses

No statistical analyses for this end point

Secondary: Heart rate taken during vital signs assessment

| | |
|---|--|
| End point title | Heart rate taken during vital signs assessment |
| End point description: Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 | |

compared with placebo, in adult subjects with moderate-to-severe AD.

| | |
|-------------------------------|-----------|
| End point type | Secondary |
| End point timeframe: | |
| Baseline, week 16 and week 24 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Pulse Rate (beats/min) | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 68.1 (± 9.8) | 66.6 (± 8.7) | 71.3 (± 9.3) | 68.2 (± 11.1) |
| Week 16 | 69.4 (± 10.1) | 66.9 (± 10.6) | 65.9 (± 8.6) | 66.4 (± 11.0) |
| Week 24 | 72.0 (± 13.5) | 67.0 (± 10.4) | 74.1 (± 8.7) | 67.6 (± 10.1) |

Statistical analyses

No statistical analyses for this end point

Secondary: Respiratory rate collected during vital signs assessment

| | |
|--|--|
| End point title | Respiratory rate collected during vital signs assessment |
| End point description: | |
| Collectively with other vital signs assessment are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, week 16 and week 24 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: breaths/min | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 15.4 (± 2.2) | 16.0 (± 1.5) | 16.2 (± 1.8) | 15.5 (± 1.8) |
| Week 16 | 16.0 (± 2.3) | 15.7 (± 1.8) | 16.3 (± 1.9) | 15.9 (± 1.4) |
| Week 24 | 15.8 (± 2.4) | 16.1 (± 1.5) | 17.1 (± 2.4) | 15.6 (± 1.6) |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology

| | |
|--|---|
| End point title | Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Haematology |
| End point description: To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD. | |
| End point type | Secondary |
| End point timeframe: up to 24 weeks | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| Basophil AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Eosinophil AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Hematocrit AtLeastOne PostBaseline Value BelowLLN | 4 | 3 | 2 | 7 |
| Hb AtLeastOne PostBaseline Value BelowLLN | 5 | 1 | 3 | 8 |
| Lymphocyte AtLeastOne PostBaseline Value BelowLLN | 6 | 0 | 3 | 10 |
| Monocyte AtLeastOne PostBaseline Value BelowLLN | 1 | 0 | 1 | 3 |
| Platelet AtLeastOne PostBaseline Value BelowLLN | 1 | 1 | 0 | 0 |
| Erythrocyte AtLeastOne PostBaseline Value BelowLLN | 10 | 3 | 4 | 17 |
| WCC AtLeastOne PostBaseline Value BelowLLN | 7 | 1 | 2 | 6 |
| Basophil AtLeastOne PostBaseline Value AboveULN | 3 | 0 | 0 | 0 |
| Eosinophil AtLeastOne PostBaseline Value AboveULN | 22 | 4 | 5 | 14 |
| Hematocrit AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 1 | 0 |
| Hb AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 1 | 0 |
| Lymphocyte AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 0 | 0 |
| Monocyte AtLeastOne PostBaseline Value AboveULN | 2 | 0 | 2 | 3 |
| Platelet AtLeastOne PostBaseline Value AboveULN | 3 | 0 | 2 | 5 |
| Erythrocyte AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 0 | 0 |
| WCCT AtLeastOne PostBaseline Value AboveULN | 5 | 2 | 0 | 2 |
| Basophil Values within normal range | 53 | 19 | 18 | 55 |
| Eosinophil Values within normal range | 34 | 15 | 13 | 41 |
| Hematocrit Values within normal range | 52 | 16 | 15 | 48 |
| Hb Values within normal range | 51 | 18 | 14 | 47 |

| | | | | |
|--|----|----|----|----|
| Lymphocyte Values within normal range | 50 | 19 | 15 | 45 |
| Monocyte Values within normal range | 53 | 19 | 15 | 49 |
| Platelet Values within normal range | 52 | 18 | 16 | 50 |
| Erythrocyte Values within normal range | 46 | 16 | 14 | 38 |
| WCC Values within normal range | 44 | 16 | 16 | 47 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry

| | |
|-----------------|---|
| End point title | Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Serum Chemistry |
|-----------------|---|

End point description:

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 24 weeks

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| Albumin AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| ALP AtLeastOne PostBaseline Value BelowLLN | 3 | 0 | 0 | 2 |
| ALT AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| AST AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Bilirubin AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Urea AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Creatinine AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| GGT AtLeastOne PostBaseline Value BelowLLN | 4 | 2 | 0 | 5 |
| Potassium AtLeastOne PostBaseline Value BelowLLN | 1 | 1 | 0 | 1 |
| Sodium A LeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Albumin AtLeastOne PostBaseline Value AboveULN | 21 | 5 | 6 | 15 |
| ALP AtLeastOne PostBaseline Value AboveULN | 3 | 2 | 2 | 4 |
| ALT AtLeastOne PostBaseline Value AboveULN | 7 | 4 | 4 | 5 |

| | | | | |
|---|----|----|----|----|
| AST AtLeastOne PostBaseline Value AboveULN | 6 | 3 | 3 | 8 |
| Bilirubin AtLeastOne PostBaseline Value AboveULN | 3 | 0 | 1 | 1 |
| Urea AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 0 | 2 |
| Creatinine AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 1 | 3 |
| GGT AtLeastOne PostBaseline Value AboveULN | 2 | 3 | 2 | 1 |
| Potassium AtLeastOne PostBaseline Value AboveULN | 1 | 0 | 1 | 1 |
| Sodium AtLeastOne PostBaseline Value AboveULN | 2 | 0 | 0 | 2 |
| Albumin Values within normal range | 35 | 14 | 12 | 40 |
| ALP Values within normal range | 50 | 17 | 16 | 49 |
| ALT Values within normal range | 49 | 15 | 14 | 50 |
| AST Values within normal range | 50 | 16 | 15 | 47 |
| Bilirubin Values within normal range | 53 | 19 | 17 | 54 |
| Urea Values within normal range | 56 | 19 | 18 | 53 |
| Creatinine Values within normal range | 56 | 19 | 17 | 52 |
| GGT Values within normal range | 50 | 14 | 16 | 49 |
| Potassium Values within normal range | 54 | 18 | 17 | 53 |
| Sodium Values within normal range | 54 | 19 | 18 | 53 |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis

| | |
|-----------------|--|
| End point title | Number of Participants with Abnormal Laboratory Assessments Relative to Normal Ranges for Urinalysis |
|-----------------|--|

End point description:

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

up to 24 weeks

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: Participants | | | | |
| pH AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Erythrocyte AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| Sp gravity AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |

| | | | | |
|--|----|----|----|----|
| Leukocyte AtLeastOne PostBaseline Value BelowLLN | 0 | 0 | 0 | 0 |
| pH AtLeastOne PostBaseline Value AboveULN | 0 | 0 | 0 | 1 |
| Erythrocyte AtLeastOne PostBaseline Value AboveULN | 8 | 2 | 1 | 6 |
| Sp gravity AtLeastOne PostBaseline Value AboveULN | 4 | 0 | 3 | 7 |
| Leukocyte AtLeas One PostBaseline Value AboveULN | 4 | 2 | 1 | 5 |
| pH Values within normal range | 56 | 19 | 18 | 54 |
| Erythrocyte Values within normal range | 48 | 17 | 17 | 49 |
| Sp gravity Values within normal range | 52 | 19 | 15 | 48 |
| Leukocyte Values within normal range | 52 | 17 | 17 | 50 |

Statistical analyses

No statistical analyses for this end point

Secondary: Heart rate (beats/min) recorded on ECGs

| | |
|---|---|
| End point title | Heart rate (beats/min) recorded on ECGs |
| End point description: | |
| Collectively with other ECG parameters are used t assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD. | |
| End point type | Secondary |
| End point timeframe: | |
| Baseline, week 16 and week 24 | |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: beats per minute | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 67.59 (± 9.82) | 65.61 (± 6.87) | 72.63 (± 9.82) | 65.18 (± 9.43) |
| Week 16 | 66.02 (± 9.97) | 63.80 (± 8.56) | 65.42 (± 9.08) | 63.05 (± 10.61) |
| Week 24 | 68.17 (± 13.94) | 63.88 (± 10.41) | 72.46 (± 9.12) | 64.58 (± 9.43) |

Statistical analyses

No statistical analyses for this end point

Secondary: QT (milliseconds) recorded on ECGs

| | |
|-----------------|------------------------------------|
| End point title | QT (milliseconds) recorded on ECGs |
|-----------------|------------------------------------|

End point description:

Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline, week 16 and week 24

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|---------------------|---------------------|---------------------|---------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: milliseconds | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 385.43 (± 27.75) | 390.67 (± 20.57) | 380.04 (± 26.38) | 390.27 (± 22.69) |
| Week 16 | 387.05 (± 26.14) | 390.40 (± 24.24) | 395.75 (± 20.36) | 391.95 (± 29.22) |
| Week 24 | 385.88 (± 34.31) | 398.69 (± 28.52) | 383.15 (± 19.05) | 393.40 (± 26.54) |

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Investigator's overall ECGs evaluations, e.g. normal/abnormal and their clinical significance

| | |
|-----------------|---|
| End point title | Number of Participants with Investigator's overall ECGs evaluations, e.g. normal/abnormal and their clinical significance |
|-----------------|---|

End point description:

Collectively with other ECG parameters are used to assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16 and week 24

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: participants | | | | |
| Week 16 Abnormal ECG: Clinically significant | 0 | 0 | 0 | 0 |
| Week 24 Abnormal ECG: Clinically significant | 0 | 0 | 0 | 0 |
| Week 16 Abnormal ECG: Not Clinically significant | 3 | 2 | 2 | 10 |

| | | | | |
|--|----|----|----|----|
| Week 24 Abnormal ECG: Not Clinically significant | 4 | 4 | 2 | 11 |
| Week 16 Normal ECG | 38 | 13 | 10 | 32 |
| Week 24 Normal ECG | 38 | 12 | 11 | 29 |
| Week 16 Missing | 15 | 4 | 6 | 13 |
| Week 24 Missing | 14 | 3 | 5 | 15 |

Statistical analyses

No statistical analyses for this end point

Secondary: Left Ventricular Ejection Fraction measured by Echocardiogram

| | |
|-----------------|---|
| End point title | Left Ventricular Ejection Fraction measured by Echocardiogram |
|-----------------|---|

End point description:

To assess the safety and tolerability of MEDI3506 compared with placebo, in adult subjects with moderate-to-severe AD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Baseline and week 16

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|--------------------------------------|-----------------|-----------------|-----------------|-----------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: % LVEF | | | | |
| arithmetic mean (standard deviation) | | | | |
| Baseline | 64.3 (± 6.3) | 64.7 (± 6.2) | 62.8 (± 5.2) | 63.6 (± 4.7) |
| Week 16 | 64.3 (± 5.9) | 63.0 (± 4.4) | 61.0 (± 3.6) | 65.2 (± 5.1) |

Statistical analyses

No statistical analyses for this end point

Secondary: Serum MEDI3506 concentration profiles

| | |
|-----------------|--|
| End point title | Serum MEDI3506 concentration profiles ^[1] |
|-----------------|--|

End point description:

To evaluate the PK of MEDI3506 in adult subjects with moderate-to-severe AD.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 16 and week 24

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Placebo arm not included since this is PK

| End point values | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 | |
|---|--------------------|--------------------|--------------------|--|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 18 | 17 | 48 | |
| Units: µg/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Week 16 | 0.377 (± 242) | 2.158 (± 193) | 5.979 (± 118) | |
| Week 24 | 0.018 (± 184) | 0.118 (± 298) | 0.188 (± 234) | |

Statistical analyses

No statistical analyses for this end point

Secondary: Occurrence of Anti-drug antibody during the treatment and follow-up periods

| | |
|------------------------|--|
| End point title | Occurrence of Anti-drug antibody during the treatment and follow-up periods |
| End point description: | To evaluate the immunogenicity of MEDI3506 in adult subjects with moderate-to-severe AD. |
| End point type | Secondary |
| End point timeframe: | up to 24 weeks |

| End point values | Placebo | MEDI3506 Dose 1 | MEDI3506 Dose 2 | MEDI3506 Dose 3 |
|---|-----------------|--------------------|--------------------|--------------------|
| Subject group type | Reporting group | Reporting group | Reporting group | Reporting group |
| Number of subjects analysed | 56 | 19 | 18 | 55 |
| Units: participants | | | | |
| Number of ADA positive participants at baseline | 1 | 0 | 0 | 0 |
| Number of ADA positive participants post baseline | 1 | 1 | 0 | 2 |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

24 weeks

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 25.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|---------|
| Reporting group title | Placebo |
|-----------------------|---------|

Reporting group description:

Pooled Placebo

| | |
|-----------------------|-----------------|
| Reporting group title | MEDI3506 Dose 3 |
|-----------------------|-----------------|

Reporting group description:

MEDI3506 Dose 3 was administered SC to participants once every 4 weeks for 16 weeks

| | |
|-----------------------|-----------------|
| Reporting group title | MEDI3506 Dose 2 |
|-----------------------|-----------------|

Reporting group description:

MEDI3506 Dose 2 was administered SC to participants once every 4 weeks for 16 weeks

| | |
|-----------------------|-----------------|
| Reporting group title | MEDI3506 Dose 1 |
|-----------------------|-----------------|

Reporting group description:

MEDI3506 Dose 1 was administered SC to participants once every 4 weeks for 16 weeks

| Serious adverse events | Placebo | MEDI3506 Dose 3 | MEDI3506 Dose 2 |
|---|----------------|-----------------|-----------------|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 56 (3.57%) | 1 / 55 (1.82%) | 2 / 18 (11.11%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | | | |
| Vascular disorders | | | |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 0 / 55 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Surgical and medical procedures | | | |
| Medical device removal | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 1 / 55 (1.82%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Immune system disorders | | | |
| Food allergy | | | |

| | | | |
|---|----------------|----------------|----------------|
| subjects affected / exposed | 1 / 56 (1.79%) | 0 / 55 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis exfoliative generalised | | | |
| subjects affected / exposed | 1 / 56 (1.79%) | 0 / 55 (0.00%) | 0 / 18 (0.00%) |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Infections and infestations | | | |
| Covid-19 pneumonia | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 0 / 55 (0.00%) | 1 / 18 (5.56%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| | | | |
|---|-----------------|--|--|
| Serious adverse events | MEDI3506 Dose 1 | | |
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | | | |
| Vascular disorders | | | |
| Venous thrombosis limb | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Surgical and medical procedures | | | |
| Medical device removal | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Immune system disorders | | | |
| Food allergy | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Skin and subcutaneous tissue disorders | | | |
| Dermatitis exfoliative generalised | | | |

| | | | |
|---|----------------|--|--|
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Infections and infestations | | | |
| Covid-19 pneumonia | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences causally related to treatment / all | 0 / 0 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Placebo | MEDI3506 Dose 3 | MEDI3506 Dose 2 |
|---|------------------|------------------|------------------|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 29 / 56 (51.79%) | 25 / 55 (45.45%) | 14 / 18 (77.78%) |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 0 / 55 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| General disorders and administration site conditions | | | |
| Injection site swelling | | | |
| subjects affected / exposed | 1 / 56 (1.79%) | 0 / 55 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 4 / 55 (7.27%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 6 | 1 |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 1 / 55 (1.82%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 1 | 1 |
| Influenza like illness | | | |
| subjects affected / exposed | 1 / 56 (1.79%) | 0 / 55 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 0 / 55 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 0 | 0 | 1 |

| | | | |
|---|---|---|---|
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 3 / 56 (5.36%) 3 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Investigations Liver function test increased subjects affected / exposed occurrences (all) Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) Urine analysis abnormal subjects affected / exposed occurrences (all) | 2 / 56 (3.57%) 2 0 / 56 (0.00%) 0 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 | 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 |
| Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all) Fall subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 1 / 18 (5.56%) 1 |
| Cardiac disorders Palpitations subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Nervous system disorders Presyncope subjects affected / exposed occurrences (all) Carpal tunnel syndrome subjects affected / exposed occurrences (all) Headache | 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 | 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 |

| | | | |
|--|--|--|---|
| subjects affected / exposed occurrences (all) | 3 / 56 (5.36%) 3 | 0 / 55 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all) | 3 / 56 (5.36%) 3 | 0 / 55 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all) Aphthous ulcer subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Dry mouth subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 1 / 55 (1.82%) 1 0 / 55 (0.00%) 0 0 / 55 (0.00%) 0 1 / 55 (1.82%) 1 | 1 / 18 (5.56%) 1 0 / 18 (0.00%) 0 0 / 18 (0.00%) 0 1 / 18 (5.56%) 2 1 / 18 (5.56%) 1 |
| Skin and subcutaneous tissue disorders Dermatitis atopic subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Eczema subjects affected / exposed occurrences (all) | 12 / 56 (21.43%) 14 3 / 56 (5.36%) 3 3 / 56 (5.36%) 3 | 14 / 55 (25.45%) 17 1 / 55 (1.82%) 1 2 / 55 (3.64%) 3 | 0 / 18 (0.00%) 0 2 / 18 (11.11%) 2 2 / 18 (11.11%) 2 |
| Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |

| | | | |
|---|---------------------|---------------------|----------------------|
| Pain in extremity subjects affected / exposed occurrences (all) | 1 / 56 (1.79%) 1 | 0 / 55 (0.00%) 0 | 2 / 18 (11.11%) 3 |
| Infections and infestations | | | |
| Cellulitis subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 2 |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Acarodermatitis subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 0 / 18 (0.00%) 0 |
| Conjunctivitis subjects affected / exposed occurrences (all) | 1 / 56 (1.79%) 1 | 1 / 55 (1.82%) 1 | 1 / 18 (5.56%) 1 |
| Urinary tract infection subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 | 1 / 18 (5.56%) 1 |
| Otitis externa subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 1 / 55 (1.82%) 1 | 1 / 18 (5.56%) 1 |
| Oral herpes subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 2 |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 1 / 56 (1.79%) 1 | 3 / 55 (5.45%) 3 | 2 / 18 (11.11%) 2 |
| Influenza subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Gastroenteritis viral subjects affected / exposed occurrences (all) | 0 / 56 (0.00%) 0 | 0 / 55 (0.00%) 0 | 1 / 18 (5.56%) 1 |
| Eczema infected | | | |

| | | | |
|-----------------------------|-----------------|----------------|----------------|
| subjects affected / exposed | 1 / 56 (1.79%) | 0 / 55 (0.00%) | 1 / 18 (5.56%) |
| occurrences (all) | 1 | 0 | 1 |
| Dermatitis infected | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 0 / 55 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Folliculitis | | | |
| subjects affected / exposed | 0 / 56 (0.00%) | 0 / 55 (0.00%) | 0 / 18 (0.00%) |
| occurrences (all) | 0 | 0 | 0 |
| Covid-19 | | | |
| subjects affected / exposed | 7 / 56 (12.50%) | 2 / 55 (3.64%) | 0 / 18 (0.00%) |
| occurrences (all) | 7 | 2 | 0 |

| | | | |
|---|------------------|--|--|
| Non-serious adverse events | MEDI3506 Dose 1 | | |
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 11 / 19 (57.89%) | | |
| Vascular disorders | | | |
| Hypotension | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| General disorders and administration site conditions | | | |
| Injection site swelling | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |
| Injection site bruising | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |
| Influenza like illness | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Oropharyngeal pain | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |

| | | | |
|---|---|--|--|
| Dyspnoea subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Psychiatric disorders Insomnia subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Investigations Liver function test increased subjects affected / exposed occurrences (all) Gamma-glutamyltransferase increased subjects affected / exposed occurrences (all) Urine analysis abnormal subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 1 / 19 (5.26%) 1 1 / 19 (5.26%) 1 | | |
| Injury, poisoning and procedural complications Arthropod bite subjects affected / exposed occurrences (all) Fall subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 0 / 19 (0.00%) 0 | | |
| Cardiac disorders Palpitations subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Nervous system disorders Presyncope subjects affected / exposed occurrences (all) Carpal tunnel syndrome subjects affected / exposed occurrences (all) Headache | 1 / 19 (5.26%) 1 1 / 19 (5.26%) 1 | | |

| | | | |
|--|---|--|--|
| subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Ear and labyrinth disorders Ear pain subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all) Aphthous ulcer subjects affected / exposed occurrences (all) Nausea subjects affected / exposed occurrences (all) Dry mouth subjects affected / exposed occurrences (all) Diarrhoea subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 1 / 19 (5.26%) 1 1 / 19 (5.26%) 1 0 / 19 (0.00%) 0 0 / 19 (0.00%) 0 | | |
| Skin and subcutaneous tissue disorders Dermatitis atopic subjects affected / exposed occurrences (all) Pruritus subjects affected / exposed occurrences (all) Eczema subjects affected / exposed occurrences (all) | 2 / 19 (10.53%) 2 1 / 19 (5.26%) 1 0 / 19 (0.00%) 0 | | |
| Musculoskeletal and connective tissue disorders Myalgia subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |

| | | | |
|---|---------------------|--|--|
| Pain in extremity subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Infections and infestations | | | |
| Cellulitis subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Bronchitis subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Acarodermatitis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Conjunctivitis subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Urinary tract infection subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Otitis externa subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Oral herpes subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Nasopharyngitis subjects affected / exposed occurrences (all) | 1 / 19 (5.26%) 1 | | |
| Influenza subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Gastroenteritis viral subjects affected / exposed occurrences (all) | 0 / 19 (0.00%) 0 | | |
| Eczema infected | | | |

| | | | |
|-----------------------------|----------------|--|--|
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |
| Dermatitis infected | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Folliculitis | | | |
| subjects affected / exposed | 1 / 19 (5.26%) | | |
| occurrences (all) | 1 | | |
| Covid-19 | | | |
| subjects affected / exposed | 0 / 19 (0.00%) | | |
| occurrences (all) | 0 | | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-------------------|-------------|
| 01 October 2019 | Amendment 1 |
| 24 October 2019 | Amendment 2 |
| 13 January 2020 | Amendment 3 |
| 27 March 2020 | Amendment 4 |
| 03 June 2020 | Amendment 5 |
| 07 September 2020 | Amendment 6 |
| 29 October 2020 | Amendment 7 |
| 23 February 2021 | Amendment 8 |
| 15 June 2022 | Amendment 9 |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date | Interruption | Restart date |
|---------------|---|--------------|
| 26 March 2020 | Subject recruitment was temporarily placed on hold on 26 March 2020 due to COVID-19 pandemic. Subject recruitment was restarted on a site-by-site basis after gaining regulatory and ethical approval of Protocol Amendment 5 and reviewing the local epidemiological situation and the ability of each site to safely conduct the study in the new circumstances | 03 June 2020 |

Notes:

Limitations and caveats

None reported